221 related articles for article (PubMed ID: 17849460)
1. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
[TBL] [Abstract][Full Text] [Related]
2. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
7. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles FJ; Faderl S; Kantarjian HM
Blood; 2001 Sep; 98(6):1708-13. PubMed ID: 11535501
[TBL] [Abstract][Full Text] [Related]
9. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
10. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Quintás-Cardama A; Kantarjian HM; Giles F; Verstovsek S
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):409-16. PubMed ID: 16810616
[TBL] [Abstract][Full Text] [Related]
14. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
15. Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α.
Aruna ; Li L
Med Sci Monit; 2018 Apr; 24():2302-2309. PubMed ID: 29693647
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
17. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
18. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
Song YQ; Li W; Kong LH; Wang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
20. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
Müller-Tidow C; Kiehl M; Sindermann JR; Probst M; Banger N; Zühlsdorf M; Chou TC; Berdel WE; Serve H; Koch OM
Int J Oncol; 2003 Jul; 23(1):151-8. PubMed ID: 12792788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
